ATRX immunohistochemistry can help refine ‘not elsewhere classified’ categorisation for grade II/III gliomas
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
ATRX immunohistochemistry can help refine ‘not elsewhere classified’ categorisation for grade II/III gliomas
Authors
Keywords
-
Journal
BRITISH JOURNAL OF NEUROSURGERY
Volume -, Issue -, Pages 1-5
Publisher
Informa UK Limited
Online
2019-04-25
DOI
10.1080/02688697.2019.1600657
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant
- (2018) David N. Louis et al. ACTA NEUROPATHOLOGICA
- cIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC)
- (2018) David N. Louis et al. ACTA NEUROPATHOLOGICA
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
- (2016) David N. Louis et al. ACTA NEUROPATHOLOGICA
- ATRX in Diffuse Gliomas With its Mosaic/Heterogeneous Expression in a Subset
- (2016) Suvendu Purkait et al. BRAIN PATHOLOGY
- Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas
- (2015) Yuchen Jiao et al. Oncotarget
- Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma
- (2015) Kasthuri Kannan et al. Oncotarget
- Oligoastrocytomas: throwing the baby out with the bathwater?
- (2014) Paul Wilcox et al. ACTA NEUROPATHOLOGICA
- Farewell to oligoastrocytoma: response to letters
- (2014) Felix Sahm et al. ACTA NEUROPATHOLOGICA
- Mixed glioma with molecular features of composite oligodendroglioma and astrocytoma: a true “oligoastrocytoma”?
- (2014) Jason T. Huse et al. ACTA NEUROPATHOLOGICA
- ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma
- (2014) David E. Reuss et al. ACTA NEUROPATHOLOGICA
- ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis
- (2013) Benedikt Wiestler et al. ACTA NEUROPATHOLOGICA
- Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma
- (2013) R. C. Laxton et al. NEURO-ONCOLOGY
- Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations
- (2012) Xiao-Yang Liu et al. ACTA NEUROPATHOLOGICA
- A Pyrosequencing-Based Assay for the Rapid Detection of IDH1 Mutations in Clinical Samples
- (2010) Prashanth Setty et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas
- (2010) C. Houillier et al. NEUROLOGY
- Monoclonal antibody specific for IDH1 R132H mutation
- (2009) David Capper et al. ACTA NEUROPATHOLOGICA
- Characterization of R132H Mutation-specific IDH1 Antibody Binding in Brain Tumors
- (2009) David Capper et al. BRAIN PATHOLOGY
- Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas
- (2009) Marc Sanson et al. JOURNAL OF CLINICAL ONCOLOGY
- IDH1andIDH2Mutations in Gliomas
- (2009) Hai Yan et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started